Clinical Trial Update: Cold Challenge With C21 in RP [Phase 2]

View source ↗

Summary

Phase 2 trial update on C21 for Raynaud Phenomenon and Systemic Sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• C21 (C21)

Snippet

Sponsor: Vicore Pharma AB | Conditions: Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2023-05-18